CYP2C9 genotype does not affect risk of tobacco-related cancer in the general population

Cancer Epidemiology

Volumn 34, Issue 2, 2010, Pages 178-183

  Kaur Knudsen, Diljit ^a,b   Nordestgaard, Børge Grønne ^a,b,c   Bojesen, Stig Egil ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Cancer; Cytochrome P450 2C9 (CYP2C9); General population; Polycyclic aromatic hydrocarbons (PAHs); Single nucleotide polymorphism (SNP); Tobacco

Indexed keywords

CYTOCHROME P450 2C9; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PANCREAS CANCER; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; STOMACH CANCER; TOBACCO; TOBACCO DEPENDENCE; UTERINE CERVIX CANCER; COCARCINOGENESIS; COHORT ANALYSIS; DENMARK; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASMS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; COCARCINOGENESIS; COHORT STUDIES; DENMARK; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SMOKING; CYTOCHROME P-450 CYP2C9;

EID: 77950296739     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.01.003     Document Type: Article

References (28)

1. The health consequences of smoking. A report of the Surgeon General, Office of the Surgeon General (2004), p. 1-921.
2. Ding Y.S., Ashley D.L., and Watson C.H. Determination of 10 carcinogenic polycyclic aromatic hydrocarbons in mainstream cigarette smoke. J Agric Food Chem 55 15 (2007) 5966-5973
3. Nebert D.W., and Russell D.W. Clinical importance of the cytochromes P450. Lancet 360 9340 (2002) 1155-1162
4. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21 4 (2006) 257-276
5. Shou M., Krausz K.W., Gonzalez F.J., and Gelboin H.V. Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450. Arch Biochem Biophys 328 1 (1996) 201-207
6. Boffetta P., Jourenkova N., and Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8 3 (1997) 444-472
7. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54 10 (2002) 1257-1270
8. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., and Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6 5 (1996) 429-439
9. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52 4 (2001) 349-355
10. Klein T.E., Altman R.B., Eriksson N., Gage B.F., Kimmel S.E., Lee M.T., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360 8 (2009) 753-764
11. Schwarz U.I., Ritchie M.D., Bradford Y., Li C., Dudek S.M., Frye-Anderson A., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358 10 (2008) 999-1008
12. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 3 (2007) 299-308
13. Schnohr P., Jensen J.S., Scharling H., and Nordestgaard B.G. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 23 8 (2002) 620-626
14. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., Sethi A.A., Remaley A.T., Schnohr P., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299 21 (2008) 2524-2532
15. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., and Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359 18 (2008) 1897-1908
16. Allin K.H., Bojesen S.E., and Nordestgaard B.G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27 13 (2009) 2217-2224
17. Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. Integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 95 15 (2003) 1150-1157
18. Johansen J.S., Bojesen S.E., Mylin A.K., Frikke-Schmidt R., Price P.A., and Nordestgaard B.G. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 27 4 (2009) 572-578
19. Lee J., Nordestgaard B.G., and Dahl M. Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity. Respir Med 103 9 (2009) 1286-1292
20. London S.J., Daly A.K., Leathart J.B., Navidi W.C., and Idle J.R. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 6 6 (1996) 527-533
21. London S.J., Sullivan-Klose T., Daly A.K., and Idle J.R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 7 5 (1997) 401-404
22. Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Rodriguez-Lescure A., and Agundez J.A. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett 180 1 (2002) 41-46
23. Fortuny J., Kogevinas M., Garcia-Closas M., Real F.X., Tardon A., Garcia-Closas R., et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 15 9 (2006) 1696-1702
24. Cotterchio M., Boucher B.A., Manno M., Gallinger S., Okey A.B., and Harper P.A. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17 11 (2008) 3098-3107
25. Martinez C., Garcia-Martin E., Ladero J.M., Sastre J., Garcia-Gamito F., az-Rubio M., et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22 8 (2001) 1323-1326
26. McGreavey L.E., Turner F., Smith G., Boylan K., Timothy B.D., Forman D., et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 15 10 (2005) 713-721
27. Siemes C., Eijgelsheim M., Dieleman J.P., van Schaik R.H., Uitterlinden A.G., van Duijn C.M., et al. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Neth J Med 67 4 (2009) 134-141
28. Tranah G.J., Chan A.T., Giovannucci E., Ma J., Fuchs C., and Hunter D.J. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians'. Health Study Mol Carcinog 44 1 (2005) 21-30